Description
Minoxihead-D
Minoxihead-D is presented as an oral combination containing minoxidil and dutasteride. The exact trade name could not be verified in major regulatory drug-label sources, so the summary below is based on the two active ingredients rather than on a confirmed branded product label. Minoxidil and dutasteride are both medicines that have been studied in hair-loss treatment, but their approved uses differ from androgenetic alopecia in many countries.
Active Ingredient and Medicine Class
Minoxidil is a peripheral vasodilator. When used orally, it acts on blood vessels and is primarily known as an antihypertensive medicine. In hair-loss practice, low-dose oral minoxidil has been used off label.
Dutasteride is a 5-alpha-reductase inhibitor. It reduces the conversion of testosterone to dihydrotestosterone, a hormone involved in androgen-related hair follicle miniaturisation.
Established Medical Uses
Oral minoxidil is officially used for severe or resistant hypertension, not for routine hair-loss treatment. Dutasteride is officially used for symptomatic benign prostatic hyperplasia in men with an enlarged prostate. The combination of minoxidil and dutasteride is not an established standard approved treatment for androgenetic alopecia in the official sources reviewed here.
How It Works
Minoxidil may support hair growth by prolonging the growth phase of hair follicles and increasing follicular activity, although the exact mechanism in hair treatment is not fully established. Dutasteride lowers dihydrotestosterone levels, which may reduce the hormonal drive behind progressive pattern hair thinning. Because they act through different pathways, the two ingredients are sometimes considered together in hair-loss research.
Important Safety Information
Oral minoxidil can cause marked cardiovascular effects, including changes in blood pressure, rapid heartbeat, fluid retention and increased cardiac workload. It has important interaction concerns with antihypertensive medicines and is generally associated with close medical supervision in its approved use.
Dutasteride is contraindicated in pregnancy and in women of childbearing potential because of the risk of harm to a male fetus. It may also lower prostate-specific antigen values, which can affect interpretation of prostate screening tests. Important cautions include hypersensitivity to 5-alpha-reductase inhibitors and clinically significant exposure risk from capsule contents.
Because this product combines two active ingredients with distinct systemic effects, safety considerations may be broader than with a single-ingredient hair-loss medicine. It should not be assumed to have a routine cosmetic safety profile.
Possible Side Effects
Minoxidil may cause dizziness, tachycardia, edema, and other cardiovascular or fluid-retention effects. Less commonly, serious reactions can include severe hypotension or worsening heart-related symptoms.
Dutasteride may cause sexual adverse effects, breast tenderness or enlargement, and hypersensitivity reactions. Reported serious concerns also include pregnancy-related fetal risk and clinically relevant changes in prostate cancer screening markers.
Scientific Evidence
Human research supports low-dose oral minoxidil as an off-label option for some patients with hair loss, but available studies remain limited and larger randomized trials are still needed. Dutasteride has also shown activity in androgenetic alopecia research, with reviews suggesting benefit in male pattern hair loss, while emphasizing the need for better-standardized trials. Evidence for the specific oral combination of minoxidil plus dutasteride is much less established than evidence for each ingredient separately.
Medical Information Notice
This page is an educational summary based on sources available at the time of review. It does not replace the official prescribing information, patient leaflet, or an individual assessment by a qualified healthcare professional.
Medical Sources
- U.S. Food and Drug Administration / DailyMed. Minoxidil tablet, oral prescribing information. View official label
- U.S. Food and Drug Administration / DailyMed. Dutasteride capsule, oral prescribing information. View official label
- Michael Randolph, Antonella Tosti. Oral minoxidil treatment for hair loss: A review of efficacy and safety. Journal of the American Academy of Dermatology, 2021. View scientific article
- Yunbu Ding et al. Dutasteride for the Treatment of Androgenetic Alopecia: An Updated Review. Dermatology, 2024. View scientific article
